References
- Gieseler F, Ungefroren H, Settmacher U, et al. Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal 2013;11:86
- Chu HW, Cheng CW, Chou WC, et al. A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. Hum Mol Genet 2014;23:355–67
- Gratio V, Beaufort N, Seiz L, et al. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. AmJ Pathol 2010;176:1452–61
- Chay CH, Cooper CR, Gendernalik JD, et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002;60:760–5
- Bangham J. Moving PARts. Nat Rev Cancer 2005;5:247
- Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med 1998;4:909–14
- Even-Ram SC, Maoz M, Pokroy E, et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the αvβ5 integrin. J Biol Chem 2001;276:10952–62
- Bar-Shavit R, Benezra M, Sabbah V, et al. Thrombin as a multifunctional protein: induction of cell adhesion and proliferation. Am J Respir Cell Mol Biol 1992;6:123–30
- Henrikson KP, Salazar SL, Fenton JW II, Pentecost BT. Role of thrombin receptor in breast cancer invasiveness. Br J Cancer 1999;79:401–6
- Arribas J. Matrix metalloprotease and tumor invasion. N Eng J Med 2005;352:2020–1
- Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303–13
- Schumacher M, Kelkel M, Dicato M, Diederich M. Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer. Biotechnol Adv 2011;29:531–47
- Orlikova B, Diederich M. Power from the garden: plant compounds as inhibitors of the hallmarks of cancer. Curr Med Chem 2012;19:2061–87
- Remesh A. Toxicities of anticancer drugs and its management. Int J Basic Clin Pharmacol 2012;1:2–12
- Fujimoto D, Hirono Y, Goi T, et al. The activation of Proteinase-Activated Receptor-1 (PAR1) mediates gastric cancer cell proliferation and invasion. BMC Cancer 2010;10:443
- Russo M, Spagnuolo C, Tedesco I, Russo GL. Phytochemicals in cancer prevention and therapy: truth or dare? Toxins (Basel) 2010;2:517–51
- Zhang C, Srinivasan Y, Arlow DH, et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 2012;492:387–92
- Mangal M, Sagar P, Singh H, et al. NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database. Nucleic Acids Res 2013;41:D1124–9
- Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aid Mol Des 2013;27:221–34
- Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177–96
- Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9
- Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49
- García-Lopez MT, Gutierrez-Rodríguez M, Herranz R. Thrombin-activated receptors: promising targets for cancer therapy? Curr Med Chem 2010;17:109–28
- Han N, Jin K, He K, et al. Protease-activated receptors in cancer: a systematic review. Oncol Lett 2011;2:599–608
- Kumari KK, Setty OH. Protective effect of Phyllanthus fraternus against mitochondrial dysfunction induced by co-administration of cisplatin and cyclophosphamide. J Bioenerg Biomembr 2012;44:179–88
- Kavita Kumari K, Setty OH. The protective effect of Berberis aristata against mitochondrial dysfunction induced due to co-administration of mitomycin C and cisplatin. J Cancer Sci Ther 2012;4:199–206
- Pramanik KC, Pandey AK. Natural compounds: prospective of chemoprevention. Endocrinol Metab 2013;Synd 2:e115
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997;23:3–25
- Deng Z, Chuaqui C, Singh J, et al. Novel method for analyzing three-dimensional protein-ligand binding interactions. J Med Chem 2004;47:337–44